Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 29, 2015

View Archived Issues

BGT-1-selective compound SBV-114 has anticonvulsant properties

Theravance Biopharma and Trek Therapeutics begin phase IIa trial of TD-6450

Quark Pharmaceutical begins patient recruitment for global pivotal study of QPI-1007

Amgen and Cytokinetics report topline results from COSMIC-HF

Kite Pharma partners with Alpine Immune Sciences to develop cancer immunotherapies

KaloBios starts phase I trial of KB-003 in patients with CMML

XBiotech to develop oral monoclonal antibody therapy for C. difficile infection

GSK's shingles vaccine containing QS-21 Stimulon shows efficacy against shingles

Ipsen and Telesta sign license agreement for MCNA in Europe and other territories

Cabaletta improves swallowing and muscle strength in phase II trial in OPMD

Absorb heart stent meets primary endpoints in ABSORB III and ABSORB China trials

Bristol-Myers Squibb updates pipeline progress of third quarter 2015

Effects of alemtuzumab in slowing brain volume loss in CARE MS I and II extension study

MVA-BN Filo enhances antibody response to Ebola vaccine candidate

LEO-43204 is effective for treating actinic keratosis on the face and chest

Drosophila cell line-derived Ebola vaccine

Sichuan Haisco Pharmaceutical divulges dual EGFR and HER2 inhibitors

U.S. and Italian team reports development of FAAH inhibitors

Almirall introduces TRPA1 antagonists

NicOx discloses NO donors

University of North Carolina reports MerTK/TYRO3 inhibitors

GSK provides update on LATITUDE-TIMI 60 trial

Gilead submits NDA for fixed-dose combination of sofosbuvir/velpatasvir for HCV

FDA approves Yervoy for adjuvant treatment of fully resected stage III melanoma

World Stroke Day: Neuroprotective microRNA, post-stroke recovery protein identified

LOXO-101 selected for NCI targeted therapy trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Jiangsu Nhwa Pharmaceutical patents new κ-opioid receptor antagonists
BioWorld Science
Jiangsu Nhwa Pharmaceutical Co. Ltd. has disclosed κ-opioid receptor antagonists that are potentially useful for the treatment of neurological disorders.